Investigating how a protein affects the processing of Alzheimer's-related molecules
Official title: The role of tetraspanin-regulated endolysosomal trafficking in Alzheimer's Disease
Funded at Oklahoma Medical Research Foundation · NIH-10806358 · Data updated 2026-11-12
This study is looking at how a protein called CD151 affects the way certain molecules related to Alzheimer's disease are handled in the body, which could help us understand how the disease starts and progresses, and ultimately lead to new treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma Medical Research Foundation NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | September 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $252,750 |
| NIH project number | 1R21AG085486-01 |
| Project ID | NIH-10806358 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for or diagnosed with Alzheimer's disease, particularly those with late-onset forms.
✕Less likely to help
Patients with early-onset Alzheimer's or those with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research explores the role of a protein called CD151 in the endolysosomal trafficking of molecules related to Alzheimer's disease. By examining how CD151 influences the processing of amyloid precursor protein (APP) and its degradation, the study aims to uncover mechanisms that may contribute to the onset and progression of Alzheimer's disease. The research involves both laboratory experiments and animal models to assess the effects of CD151 removal on APP processing and related inflammation. Patients may benefit from insights gained into how Alzheimer's develops, potentially leading to new therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to new approaches for preventing or treating Alzheimer's disease.
How similar studies have gone: Previous research has shown that targeting endolysosomal pathways can impact Alzheimer's pathology, suggesting this approach may yield valuable insights.
Where this research is happening
-
Oklahoma Medical Research Foundation
Oklahoma City, United States Active
Researchers
- Principal investigator: Rice, Heather C. — Oklahoma Medical Research Foundation
- Study coordinator: Rice, Heather C.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.